These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 15279847)
1. From magic bullets to designed multiple ligands. Morphy R; Kay C; Rankovic Z Drug Discov Today; 2004 Aug; 9(15):641-51. PubMed ID: 15279847 [TBL] [Abstract][Full Text] [Related]
5. Expediting drug discovery: recent advances in fast medicinal chemistry--optimization of hits and leads. Edwards PJ; Allart B; Andrews MJ; Clase JA; Menet C Curr Opin Drug Discov Devel; 2006 Jul; 9(4):425-44. PubMed ID: 16889227 [TBL] [Abstract][Full Text] [Related]
6. Metal complexes in medicinal chemistry: new vistas and challenges in drug design. Thompson KH; Orvig C Dalton Trans; 2006 Feb; (6):761-4. PubMed ID: 16437168 [TBL] [Abstract][Full Text] [Related]
7. Ligand efficiency indices as guideposts for drug discovery. Abad-Zapatero C; Metz JT Drug Discov Today; 2005 Apr; 10(7):464-9. PubMed ID: 15809192 [No Abstract] [Full Text] [Related]
8. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Zhao H Drug Discov Today; 2007 Feb; 12(3-4):149-55. PubMed ID: 17275735 [TBL] [Abstract][Full Text] [Related]
9. Calculation and application of activity discriminants in lead optimization. Luo X; Krumrine JR; Shenvi AB; Pierson ME; Bernstein PR J Mol Graph Model; 2010 Nov; 29(3):372-81. PubMed ID: 20800520 [TBL] [Abstract][Full Text] [Related]
11. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Zhan P; Liu X Curr Pharm Des; 2009; 15(16):1893-917. PubMed ID: 19519431 [TBL] [Abstract][Full Text] [Related]
12. Structural basis of the drug-binding specificity of human serum albumin. Ghuman J; Zunszain PA; Petitpas I; Bhattacharya AA; Otagiri M; Curry S J Mol Biol; 2005 Oct; 353(1):38-52. PubMed ID: 16169013 [TBL] [Abstract][Full Text] [Related]
13. "Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept? Bender A; Jenkins JL; Glick M; Deng Z; Nettles JH; Davies JW J Chem Inf Model; 2006; 46(6):2445-56. PubMed ID: 17125186 [TBL] [Abstract][Full Text] [Related]
14. Comparison of 2D fingerprint methods for multiple-template similarity searching on compound activity classes of increasing structural diversity. Tovar A; Eckert H; Bajorath J ChemMedChem; 2007 Feb; 2(2):208-17. PubMed ID: 17143917 [TBL] [Abstract][Full Text] [Related]
15. Screening for positive allosteric modulators of biological targets. Groebe DR Drug Discov Today; 2006 Jul; 11(13-14):632-9. PubMed ID: 16793532 [TBL] [Abstract][Full Text] [Related]
16. How well do medicinal chemists learn from experience? Cheshire DR Drug Discov Today; 2011 Sep; 16(17-18):817-21. PubMed ID: 21704183 [TBL] [Abstract][Full Text] [Related]
17. Benzimidazolone-based serotonin 5-HT1A or 5-HT7R ligands: synthesis and biological evaluation. Badarau E; Suzenet F; Bojarski AJ; Fînaru AL; Guillaumet G Bioorg Med Chem Lett; 2009 Mar; 19(6):1600-3. PubMed ID: 19237285 [TBL] [Abstract][Full Text] [Related]